Structural Brain Abnormalities in Patients with Parkinson Disease: A Comparative Voxel-Based Analysis Using T1-Weighted MR Imaging and Magnetization Transfer Imaging

References

1. 1.↵
   1. Braak H,
   2. Del Tredici K,
   3. Rub U,
   4. et al

   . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Braak H,
   2. Rub U,
   3. Jansen Steur EN,
   4. et al

   . Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404–10

   Abstract/FREE Full Text
3. 3.↵
   1. Mattila PM,
   2. Roytta M,
   3. Torikka H,
   4. et al

   . Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol 1998;95:576–82

   CrossRefPubMed
4. 4.↵
   1. Gomperts SN,
   2. Rentz DM,
   3. Moran E,
   4. et al

   . Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903–10

   Abstract/FREE Full Text
5. 5.↵
   1. Burton EJ,
   2. McKeith IG,
   3. Burn DJ,
   4. et al

   . Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127(pt 4):791–800

   Abstract/FREE Full Text
6. 6.↵
   1. Nagano-Saito A,
   2. Washimi Y,
   3. Arahata Y,
   4. et al

   . Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005;64:224–29

   Abstract/FREE Full Text
7. 7.↵
   1. Summerfield C,
   2. Junque C,
   3. Tolosa E,
   4. et al

   . Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005;62:281–85

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Beyer MK,
   2. Janvin CC,
   3. Larsen JP,
   4. et al

   . A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. J Neurol Neurosurg Psychiatry 2007;78:254–59

   Abstract/FREE Full Text
9. 9.↵
   1. Bouchard TP,
   2. Malykhin N,
   3. Martin WR,
   4. et al

   . Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008;29:1027–39

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Jokinen P,
    2. Bruck A,
    3. Aalto S,
    4. et al

    . Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15:88–93

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Dalaker TO,
    2. Larsen JP,
    3. Bergsland N,
    4. et al

    . Brain atrophy and white matter hyperintensities in early Parkinson's disease (a). Mov Disord 2009;24:2233–41

    CrossRefPubMed
12. 12.↵
    1. Scherfler C,
    2. Schocke MF,
    3. Seppi K,
    4. et al

    . Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain 2006;129(pt 2):538–42

    Abstract/FREE Full Text
13. 13.↵
    1. Karagulle Kendi AT,
    2. Lehericy S,
    3. Luciana M,
    4. et al

    . Altered diffusion in the frontal lobe in Parkinson disease. AJNR Am J Neuroradiol 2008;29:501–05. Epub 2008 Jan 17

    Abstract/FREE Full Text
14. 14.↵
    1. Ramio-Torrenta L,
    2. Sastre-Garriga J,
    3. Ingle GT,
    4. et al

    . Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry 2006;77:40–45

    Abstract/FREE Full Text
15. 15.↵
    1. Gass A,
    2. Barker GJ,
    3. Kidd D,
    4. et al

    . Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol 1994;36:62–67

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Filippi M,
    2. Rocca MA

    . Magnetization transfer magnetic resonance imaging in the assessment of neurological diseases. J Neuroimaging 2004;14:303–13

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Eckert T,
    2. Sailer M,
    3. Kaufmann J,
    4. et al

    . Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 2004;21:229–35

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Tambasco N,
    2. Pelliccioli GP,
    3. Chiarini P,
    4. et al

    . Magnetization transfer changes of grey and white matter in Parkinson's disease. Neuroradiology 2003;45:224–30

    PubMedWeb of Science
19. 19.↵
    1. Hoehn MM,
    2. Yahr MD

    . Parkinsonism: onset, progression and mortality. Neurology 1967;17:427–42

    FREE Full Text
20. 20.↵
    1. Fahn SR,
    2. Elton RL,
    3. Marsden CD,
    4. et al

    . Unified Parkinson's Disease Rating Scale: Recent Developments in Parkinson's Disease. London, UK: Macmillan; 1987
21. 21.↵
    1. Hilker R,
    2. Schweitzer K,
    3. Coburger S,
    4. et al

    . Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378–82

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Gibb WR,
    2. Lees AJ

    . The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745–52

    Abstract/FREE Full Text
23. 23.↵
    1. Folstein MF,
    2. Folstein SE,
    3. McHugh PR

    . “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Good CD,
    2. Johnsrude IS,
    3. Ashburner J,
    4. et al

    . A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14(1 pt 1):21–36

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Adachi M,
    2. Hosoya T,
    3. Haku T,
    4. et al

    . Evaluation of the substantia nigra in patients with Parkinsonian syndrome accomplished using multishot diffusion-weighted MR imaging. AJNR Am J Neuroradiol 1999;20:1500–06

    Abstract/FREE Full Text
26. 26.↵
    1. Dejerine

    , ed. Anatomie des Centres Nerveux. Paris, France: Masson; 1980
27. 27.↵
    1. Walter B,
    2. Blecker C,
    3. Kirsch P,
    4. et al

    . MARINA: an easy to use tool for the creation of MAsks for Region of INterest Analyses. In: Proceedings of the 9th International Conference on Functional Mapping of the Human Brain, June 19–22, 2003; New York
28. 28.↵
    1. Jahanshahi M,
    2. Jones CR,
    3. Dirnberger G,
    4. et al

    . The substantia nigra pars compacta and temporal processing. J Neurosci 2006;26:12266–73

    Abstract/FREE Full Text
29. 29.↵
    1. Menke RA,
    2. Scholz J,
    3. Miller KL,
    4. et al

    . MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009;47:435–41

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Olanow CW,
    2. Kieburtz K

    . Defining disease-modifying therapies for PD: a road map for moving forward. Mov Disord 2010;25:1774–79

    CrossRefPubMedWeb of Science